The clinical performance of three rapidly performed tests--tap test, TDx Fetal Lung Maturity and amniotic fluid absorbance at 650 nm--in predicting fetal lung maturity were evaluated in 300 samples of clear amniotic fluid. In all cases, delivery occurred within three days of sample collection. Of the 300 newborns, 44 developed respiratory distress syndrome. For the tap test, the sensitivity (95.4%), specificity (82.8%), and predictive value for maturity (99.7%) and immaturity (48.9%) were comparable to those of the TDx fetal lung maturity test: sensitivity of 100%, specificity of 88.3%, and predictive value for maturity of 100% and immaturity of 53.1%. The specificity (68.4%) and predictive value for immaturity (34.7%) of amniotic fluid absorbance at 650 nm were significantly lower than for the TDx and tap tests, whereas no significant difference was found for sensitivity and prediction of maturity between amniotic fluid absorbance at 650 nm and the TDx and tap tests. Both the tap and the TDx tests appear to be useful in antenatal assessment of fetal lung maturity in terms of reliability, rapidity and uniformity.

CancersQ2 · MEDICINE

Targeting Vesicular LGALS3BP by an Antibody-Drug Conjugate as Novel Therapeutic Strategy for Neuroblastoma

Q2 · MEDICINE

ArticleOA

Author: Sala, Gianluca ; Iacobelli, Valentina ; Di Vittorio, Giulia ; Capone, Emily ; Ponzoni, Mirco ; Ponziani, Sara ; Iezzi, Manuela ; Rossi, Cosmo ; Panella, Valeria ; Bibbò, Sandra ; De Laurenzi, Vincenzo ; Giansanti, Francesco ; Piccolo, Enza ; Iacobelli, Stefano ; Lamolinara, Alessia ; Lattanzio, Rossano ; Sala, Arturo ; Gentile, Roberta ; D’Agostino, Daniela ; Ippoliti, Rodolfo ; Sallese, Michele ; Pastorino, Fabio

Neuroblastoma is the most common extra-cranial solid tumor in infants and children, which accounts for approximately 15% of all cancer-related deaths in the pediatric population. New therapeutic modalities are urgently needed. Antibody-Drug Conjugates (ADC)s-based therapy has been proposed as potential strategy to treat this pediatric malignancy. LGALS3BP is a highly glycosylated protein involved in tumor growth and progression. Studies have shown that LGALS3BP is enriched in extracellular vesicles (EV)s derived by most neuroblastoma cells, where it plays a critical role in preparing a favorable tumor microenvironment (TME) through direct cross talk between cancer and stroma cells. Here, we describe the development of a non-internalizing LGALS3BP ADC, named 1959-sss/DM3, which selectively targets LGALS3BP expressing neuroblastoma. 1959-sss/DM3 mediated potent therapeutic activity in different types of neuroblastoma models. Notably, we found that treatments were well tolerated at efficacious doses that were fully curative. These results offer preclinical proof-of-concept for an ADC targeting exosomal LGALS3BP approach for neuroblastomas.

100 Deals associated with 1959-sss-DM3

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Melanoma	Preclinical	Italy	Universita Degli Studi Di L'Aquila	-
Neuroblastoma	Preclinical	Italy	Universita Degli Studi Di L'Aquila	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis